Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. uri icon

authors

  • Tanaka, Yoshiya
  • Meizlik, Paige
  • Roth, David A
  • Bae, Sang-Cheol
  • Bass, Damon
  • Curtis, Paula
  • Chu, Myron
  • DeRose, Kathleen
  • Ji, Beulah
  • Kurrasch, Regina
  • Lowe, Jenny

publication date

  • January 2021